为您找到相关结果约500个

你是不是要搜索 期刊Clinical+Benefit+of+Evolocumab+by+Severity+and+Extent+of+Coronary+Artery+Disease:+An+Analysis+from+FOURIER 点击跳转

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

Relationship of activin A levels with clinical presentation, extent, and severity of coronary arterydisease

Clinical Benefit of Evolocumab in Patients With a History of MI: An Analysis From FOURIER

Association of metabolic syndrome with coronary artery disease extent and severity

Relationship between arterial stiffness parameters and the extent and severity of coronary artery disease

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic RiskScore Results From the FOURIER Trial

Association between plasma leptin/adiponectin ratios with the extent and severity of coronary arterydisease

Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From theFOURIER Trial

Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronaryartery disease (EVOCABG): study protocol for a randomized controlled clinical trial

Relationship of exercise to coronary artery disease extent, severity and plaque type: A coronary computed

Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severityof coronary artery disease, and carotid artery plaque

Use of a Genetic Risk Score to Predict Coronary and Vascular Events and Benefit From Evolocumab Therapyin Patients With Atherosclerotic Disease From the FOURIER Trial

Aortic valve sclerosis is associated with the extent of coronary artery disease in stable coronary arterydisease

The relationship between the level of soluble CD40 ligand and angiographic extent and severity of coronaryartery disease

Effects of Evolocumab in Patients With Prior Percutaneous Coronary Intervention: An Analysis From theFourier Trial

为您找到相关结果约500个

共500条页码: 1/34页15条/页